P.K. Morrow
Director at LNTH
Board
About P.K. Morrow
Dr. Phuong Khanh (P.K.) Morrow, M.D., is an independent Class II director of Lantheus Holdings (LNTH), appointed effective February 1, 2025, and serves on the Science & Technology Committee; she is 51 years old and was selected for her deep expertise leading end-to-end oncology clinical development at global pharmas and biotech . She currently leads Takeda’s Oncology Therapeutic Area Unit and previously served as CMO of CRISPR Therapeutics; she trained at MD Anderson (Heme/Onc fellowship) and holds an M.D. from UT Houston .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| CRISPR Therapeutics | Chief Medical Officer | May 2022 – Jan 2024 | Led cross-functional development across hematology, oncology, diabetes, and cardiovascular programs |
| Amgen | VP & Global Therapeutic Area Head (Hematology, GI & GU Oncology, Bone Diseases) | 2012 – 2022 | Advanced multiple oncology programs; senior portfolio leadership |
| Univ. of Texas MD Anderson Cancer Center | Assistant Professor, Dept. of Breast Medical Oncology | 2006 – Feb 2012 | Academic oncology; received ASCO YIA; LBJ Chief Fellow |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Takeda | Head, Oncology Therapeutic Area Unit (OTAU) | Since Jan 2024 | Responsible for oncology R&D strategy and portfolio |
| Other public company boards | — | — | None disclosed in LNTH proxy/8‑K |
Board Governance
| Attribute | Detail |
|---|---|
| Director class/term | Class II; term expires at the 2026 annual meeting |
| Committee assignments | Science & Technology Committee (member; not chair) |
| Independence | Board determined Dr. Morrow is an independent director under Nasdaq rules |
| Appointment effective | February 1, 2025 |
| Board/committee activity context | In 2024: Board held 9 meetings; all then‑directors attended ≥75% of Board and committee meetings (pre‑appointment to LNTH) |
| Board composition | 11 directors; 9 independent as of appointment |
| Science & Technology Committee remit | Advises on scientific, medical, regulatory and IP matters; oversees related ERM; chaired by Dr. James H. Thrall |
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Board retainer (cash) | $60,000 | Pro‑rated for partial year of service; paid per standard director program |
| Science & Technology Committee member retainer (cash) | $7,500 | Pro‑rated for partial year of service |
| Reference—standard director cash schedule | $60,000 member; committee member fees as shown | Consistent with LNTH director compensation elements table |
Performance Compensation
| Grant | Grant Value | Instrument(s) | Vesting | Notes |
|---|---|---|---|---|
| Initial director equity (partial year) | $100,000 | 50% RSUs / 50% stock options | Vests in full on first anniversary of grant date | Prorated for initial 2025 service |
| Annual director equity (from 2025) | $400,000 | Equity grant under director program | Vests in full on first anniversary of grant date | Standard annual director equity program |
Unvested Holdings (Alignment Detail)
| As of | Unvested RSUs | Unvested Options | Notes |
|---|---|---|---|
| March 3, 2025 | 563 | 1,015 | Footnote confirms these were unvested; corresponds to initial grant |
Director equity awards are time‑based (no performance metrics), vesting on the first anniversary, consistent with LNTH’s director compensation design .
Other Directorships & Interlocks
| Company | Role | Overlap/Interlock Risk |
|---|---|---|
| None disclosed | — | No other public boards disclosed; reduces interlock risk |
Expertise & Qualifications
- Oncology drug development leadership across big pharma (Amgen) and emerging biotech (CRISPR Therapeutics); currently heads Takeda’s oncology R&D unit .
- Medical training and academic credentials in oncology (MD; Baylor internal medicine residency; MD Anderson Heme/Onc fellowship; awards include ASCO YIA) .
- Selected by LNTH for “deep expertise leading end‑to‑end clinical development in oncology” with a track record advancing clinical programs—well‑matched to S&T oversight .
Equity Ownership
| Holder | Beneficial Shares | Percent of Outstanding | Unvested RSUs | Unvested Options |
|---|---|---|---|---|
| P.K. Morrow | — | <1% | 563 | 1,015 |
- Director ownership guideline: each director must hold shares equal to 3x the annual director cash retainer within five years; until met, must retain 50% of after‑tax shares from vesting/exercise .
- Hedging and pledging of company stock are prohibited for directors and employees .
Governance Assessment
- Fit and effectiveness: Morrow’s oncology development background directly strengthens the Science & Technology Committee’s remit over clinical, regulatory and IP matters, improving board oversight quality in LNTH’s core areas (radiopharma oncology and diagnostics) .
- Independence and conflicts: The Board has affirmatively determined she is independent; the 8‑K states no arrangements, family relationships, or related‑party transactions requiring disclosure under Item 404(a), and she entered into a customary director indemnification agreement—governance‑standard practice .
- Ownership alignment: As a new director, she had no beneficially owned common shares as of March 3, 2025, but held unvested RSUs and options from her initial grant; director ownership guidelines (3x cash retainer within five years) and anti‑hedging/pledging policies support progressive alignment with shareholders .
- Engagement signals: While 2024 attendance stats predate her service, LNTH’s board met frequently (nine meetings) with robust committee activity; Morrow’s placement on S&T aligns her expertise to active strategic oversight areas, a favorable signal for board effectiveness .
- Potential conflict watch‑items: Morrow’s current executive role at Takeda (oncology R&D) creates potential industry adjacency; however, LNTH disclosed no related‑party dealings and standard committee/Board processes (e.g., recusals under the related‑party policy overseen by the Audit Committee) mitigate risks .
RED FLAGS: None disclosed specific to Morrow—no related‑party transactions, no hedging/pledging permitted, and independence affirmed. Monitor for future interlocks or transactions involving Takeda or prior affiliations; ensure recusal protocols are followed if counterparties overlap .